Resources


Advanced



 Quick Order
  This area of the site
   requires the
  Acrobat Reader
  and the ability to
  view zipped files.
  Click below to
  download the
   necessary
   software.
  The StuffIt
   software can be
   used for either
   Windows or
   Macintosh.


Download the Adobe Acrobat reader

Download the StuffIt Expander

Download WinZip

 
 
Slide Lecture Programs
2004 Core Curriculum
Impact of vascular biology on cardiovascular disease, risk prevention, and treatment
Section I: Atrial fibrillation, anticoagulation, and stroke prevention
April 16, 2004

E:  Emerging new options
Profile of direct thrombin inhibition" width="220" height="147" border="0">

The ideal oral anticoagulant
 
 
32
  Slide: 32 - Rationale for direct thrombin inhibition: A new anticoagulant strategy</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

Rationale for direct thrombin inhibition: A new anticoagulant strategy
 
 
33
  Slide: 33 - Prothrombotic effects of thrombin</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

Prothrombotic effects of thrombin
 
 
34
  Slide: 34 - Coagulation cascade: Central role of thrombin</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

Coagulation cascade: Central role of thrombin
 
 
35
  Slide: 35 - Thrombin binding sites</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

Thrombin binding sites
 
 
36
  Slide: 36 - Direct thrombin inhibitor specificity for the active site</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

Direct thrombin inhibitor specificity for the active site
 
 
37
  Slide: 37 - Heparins and direct thrombin inhibitors: Mechanisms of action</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

Heparins and direct thrombin inhibitors: Mechanisms of action
 
 
38
  Slide: 38 - Direct thrombin inhibitors block both circulating and clot-bound thrombin</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

Direct thrombin inhibitors block both circulating and clot-bound thrombin
 
 
39
  Slide: 39 - Characteristics of direct thrombin inhibitors
</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

Characteristics of direct thrombin inhibitors
 
 
40
  Slide: 40 - Direct thrombin inhibitors</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

Direct thrombin inhibitors
 
 
41
  Slide: 41 - Ximelagatran pharmacokinetics</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

Ximelagatran pharmacokinetics
 
 
42
  Slide: 42 - Benefits of ximelagatran</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

Benefits of ximelagatran
 
 
43
  Slide: 43 - SPORTIF III and V: Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III and V: Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation
 
 
44
  Slide: 44 - SPORTIF III and V: Objective and design</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III and V: Objective and design
 
 
45
  Slide: 45 - SPORTIF III and V: Non-inferiority testing</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III and V: Non-inferiority testing
 
 
46
  Slide: 46 - SPORTIF III and V: Inclusion criteria</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III and V: Inclusion criteria
 
 
47
  Slide: 47 - SPORTIF III: Quality of warfarin control</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III: Quality of warfarin control
 
 
48
  Slide: 48 - SPORTIF III: Primary outcome (stroke and systemic embolism)<br> Intention-to-treat analysis</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III: Primary outcome (stroke and systemic embolism)
Intention-to-treat analysis
 
 
49
  Slide: 49 - SPORTIF III: Primary outcome (stroke and systemic embolism)<br> On-treatment analysis</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III: Primary outcome (stroke and systemic embolism)
On-treatment analysis
 
 
50
  Slide: 50 - SPORTIF III: Event rate comparisons for secondary composite outcomes</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III: Event rate comparisons for secondary composite outcomes
 
 
51
  Slide: 51 - SPORTIF III: Incidence of hemorrhage</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III: Incidence of hemorrhage
 
 
52
  Slide: 52 - SPORTIF III: Incidence of liver enzyme elevation</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III: Incidence of liver enzyme elevation
 
 
53
  Slide: 53 - SPORTIF III: Net clinical benefit</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III: Net clinical benefit
 
 
54
  Slide: 54 - SPORTIF V: Quality of warfarin control</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF V: Quality of warfarin control
 
 
55
  Slide: 55 - SPORTIF V: Primary outcome (stroke and systemic embolism)<br> Intention-to-treat analysis</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF V: Primary outcome (stroke and systemic embolism)
Intention-to-treat analysis
 
 
56
  Slide: 56 - SPORTIF V: Primary and sensitivity analyses</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF V: Primary and sensitivity analyses
 
 
57
  Slide: 57 - SPORTIF V: Incidence of hemorrhage</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF V: Incidence of hemorrhage
 
 
58
  Slide: 58 - SPORTIF V: Incidence of liver enzyme elevation</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF V: Incidence of liver enzyme elevation
 
 
59
  Slide: 59 - SPORTIF III and V pooled results: Primary outcome</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III and V pooled results: Primary outcome
 
 
60
  Slide: 60 - SPORTIF III and V pooled results: Incidence of major bleeding</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III and V pooled results: Incidence of major bleeding
 
 
61
  Slide: 61 - SPORTIF III and V pooled results: Net clinical benefit</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III and V pooled results: Net clinical benefit
 
 
62
  Slide: 62 - SPORTIF III and V: Conclusions</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

SPORTIF III and V: Conclusions
 
 
63
  Slide: 63 - THRIVE III: Extended secondary prevention of VTE with ximelagatran</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

THRIVE III: Extended secondary prevention of VTE with ximelagatran
 
 
64
  Slide: 64 - THRIVE III: Incidence of hemorrhage</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

THRIVE III: Incidence of hemorrhage
 
 
65
  Slide: 65 - THRIVE III: Time course of liver enzyme elevation</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

THRIVE III: Time course of liver enzyme elevation
 
 
66
  Slide: 66 - THRIVE III: Conclusions</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

THRIVE III: Conclusions
 
 
<< previous

Home | Literature Update | Journal Link | Resources | Meeting Highlights | Members | About VBWG | Web Links